Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Finally a potentially effective therapeutic approach is to
2021-11-22

Finally, a potentially effective therapeutic approach is to target the LDH enzymes that mediate bidirectional conversion of pyruvate into lactate. In particular, because LDHA is the predominant isoform expressed in glycolytic tumours, an array of LDHA-targeting compounds have been proposed and valid
-
Finally a potentially effective therapeutic approach is to
2021-11-22

Finally, a potentially effective therapeutic approach is to target the LDH enzymes that mediate bidirectional conversion of pyruvate into lactate. In particular, because LDHA is the predominant isoform expressed in glycolytic tumours, an array of LDHA-targeting compounds have been proposed and valid
-
Human GPR hGPR was originally isolated in as an
2021-11-22

Human GPR55 (hGPR55) was originally isolated in 1999 as an orphan GPCR with high levels of expression in human striatum (Sawzdargo et al., 1999) (Genbank accession # NM_005683.3). hGPR55 was mapped to human chromosome 2q37, and in the human CNS it is predominantly localized to the caudate, putamen,
-
siRNA construction and transfection For small
2021-11-22

siRNA construction and transfection. For small interfering RNA (siRNA) experiments, we used Stealth™ select RNAi oligonucleotides targeted against GPR120 (Gibco/Invitrogen). The target sequence of siGPR120 used were; sense 5′-AAGUGGGUGCGAUUGACUUGGUCCA-3′ and antisense 5′-UGGACCAAGUCAAUCGCACCCACUU-3′
-
Introduction CD T cell recovery after
2021-11-22

Introduction CD4+ T cell recovery after initiation of combination antiretroviral therapy (cART) is essential for restoring immune function in HIV-positive individuals [1]. However, CD4 recovery is variable and is affected by factors such as biological sex [2], [3], race [4], BMI [5], geographic reg
-
Introduction Molecular imprinting technology is a method
2021-11-22

Introduction Molecular imprinting technology is a method that combines the material chemistry, biochemistry, and polymer chemistry and has the ability to specifically identify target analytes on shape, size and functional groups. Molecular imprinting polymer (MIP) is developed based on molecular im
-
Results from the current study are not
2021-11-22

Results from the current study are not consistent with those of a previous study (Poock et al., 2015) where there was no differences in ovulation induction response when there was administration of gonadorelin hydrochloride and gonadorelin diacetate salts. These differences in results are likely du
-
For several parasites of veterinary importance there
2021-11-22

For several parasites of veterinary importance, there is a growing body of evidence that resistance to ML is, at least in part, mediated by ABC transporters (P-glycoproteins) (Whittaker et al., 2017). P-glycoproteins (Pgps) are members of the ATP-binding cassette transporter family that are well kno
-
carboxypeptidase a br Restart of Stalled Replication Forks B
2021-11-22

Restart of Stalled Replication Forks By preventing the replisome from unwinding duplex DNA, ICLs stall progression of the replication fork, which in turn results in genomic instability 41., 42.. As in prokaryotes, the conventional mechanism of ICL repair in eukaryotes involves the combined activi
-
Conformational changes are observed in
2021-11-22

Conformational changes are observed in the LBDs after ligand binding, including partial cleft closure for GluN2A and complete cleft closure for GluN1. For GluN2A, additional conformational rearrangements in the protein and ligand may be required before the ligand can be accommodated within lobe 2. F
-
Ironically another series of studies examining the role of
2021-11-22

Ironically, another series of studies examining the role of EAATs in CNS injury and disease suggest that under some pathological conditions, the operation of the EAATs is not protective, but actually contributes to the excitotoxic process (Rossi et al., 2000). The transporters do so by serving as th
-
Gastric inhibitory polypeptide a hormone belonging to the gl
2021-11-22

Gastric inhibitory polypeptide, a hormone belonging to the glucagon-secretin family of peptides, exhibits protection against the neurodegeneration and also stimulates neurogenesis in adult rats in a paracrine manner (Gault and Holscher, 2008, Nyberg et al., 2005, Usdin et al., 1993). The expression
-
The waiting time for first arrival of cells into the
2021-11-22

The waiting time for first arrival of a66 mg into the dense fraction of 3–4 min at the normal chloride conductance, and about 30 min with inhibition to about 10% of the normal value, signifies that the Gardos channels in the activated cells become maximally or near maximally activated, corresponding
-
As we showed earlier a to min incubation with mM
2021-11-22

As we showed earlier [19], a 20- to 30-min incubation with 2mM t-BHP resulted in erythrocyte swelling, which was less in a Ca2+-containing medium. Given that this effect was abolished in the presence of the Gardos channel inhibitor CLT, as well as in media high in K+, we suggested the contribution f
-
Auranofin br Introduction Alzheimer s disease AD affects ca
2021-11-22

Introduction Alzheimer's disease (AD) affects ca. 46 million people worldwide [1] and it is expected that the number will double or triple by 2030 or 2050, respectively, while no significant progress has been made in research for early diagnosis and new efficient therapies. Currently available me
16087 records 561/1073 page Previous Next First page 上5页 561562563564565 下5页 Last page